Expon I

HelloBetter is a global pioneer in the field of digital therapeutics (DTx) and prescription digital therapeutics (PDTx) for mental health. Our mission is to empower people to manage and improve their mental health in a self-determined way, by allowing them to do so anywhere and at any time. The company was founded as a university-spin off in 2015 by internationally renowned research psychologists. Within the German DiGA framework, as a pioneering approach globally, HelloBetter got six online therapy programmes approved as a DiGA by the German Federal Institute for Drugs and Medical Devices (BfArM), making the digital therapeutics available on prescription and free of charge for more than 73 million people in Germany. DiGA are Prescription Digital Therapeutics that are also universally reimbursed nationwide in Germany. The six DiGA are another milestone on the company's path to making evidence-based digital mental health care accessible worldwide. Overall, HelloBetter offers 10 DTx which were evaluated in 33 randomized controlled trials (stress & burnout, diabetes & depression, chronic pain, vaginismus, panic & anxiety, insomnia, alcohol consumption, depression, stress management, depression prevention). No other provider worldwide has conducted as many clinical studies on the effectiveness of its online mental health programmes. With our €17m Series A, we push for expansion beyond the DACH region.

HelloBetter is a global pioneer in the field of digital therapeutics (DTx) and prescription digital therapeutics (PDTx) for mental health. Our mission is to empower people to manage and improve their mental health in a self-determined way, by allowing them to do so anywhere and at any time. The company was founded as a university-spin off in 2015 by internationally renowned research psychologists. Within the German DiGA framework, as a pioneering approach globally, HelloBetter got six online therapy programmes approved as a DiGA by the German Federal Institute for Drugs and Medical Devices (BfArM), making the digital therapeutics available on prescription and free of charge for more than 73 million people in Germany. DiGA are Prescription Digital Therapeutics that are also universally reimbursed nationwide in Germany. The six DiGA are another milestone on the company's path to making evidence-based digital mental health care accessible worldwide. Overall, HelloBetter offers 10 DTx which were evaluated in 33 randomized controlled trials (stress & burnout, diabetes & depression, chronic pain, vaginismus, panic & anxiety, insomnia, alcohol consumption, depression, stress management, depression prevention). No other provider worldwide has conducted as many clinical studies on the effectiveness of its online mental health programmes. With our €17m Series A, we push for expansion beyond the DACH region.

HelloBetter is a global pioneer in the field of digital therapeutics (DTx) and prescription digital therapeutics (PDTx) for mental health. Our mission is to empower people to manage and improve their mental health in a self-determined way, by allowing them to do so anywhere and at any time. The company was founded as a university-spin off in 2015 by internationally renowned research psychologists. Within the German DiGA framework, as a pioneering approach globally, HelloBetter got six online therapy programmes approved as a DiGA by the German Federal Institute for Drugs and Medical Devices (BfArM), making the digital therapeutics available on prescription and free of charge for more than 73 million people in Germany. DiGA are Prescription Digital Therapeutics that are also universally reimbursed nationwide in Germany. The six DiGA are another milestone on the company's path to making evidence-based digital mental health care accessible worldwide. Overall, HelloBetter offers 10 DTx which were evaluated in 33 randomized controlled trials (stress & burnout, diabetes & depression, chronic pain, vaginismus, panic & anxiety, insomnia, alcohol consumption, depression, stress management, depression prevention). No other provider worldwide has conducted as many clinical studies on the effectiveness of its online mental health programmes. With our €17m Series A, we push for expansion beyond the DACH region.